Exelixis reported $1.62B in Current Assets for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Acadia Pharmaceuticals ACAD:US USD 507.94M 13.62M
Agios Pharmaceuticals AGIO:US USD 832.77M 47.84M
Amgen AMGN:US USD 22.19B 1.88B
AstraZeneca AZN:LN USD 22.59B 2.37B
Bayer BAYN:GR EUR 37.76B 652M
Biomarin Pharmaceutical BMRN:US USD 2.75B 68.76M
Bluebird Bio BLUE:US USD 160.44M 7.02M
Cytokinetics CYTK:US USD 795.19M 89.09M
Eisai 4523:JP JPY 610.12B 24.74B
Esperion Therapeutics ESPR:US USD 246.68M 15.1M
Exelixis EXEL:US USD 1.62B 222.86M
Genmab GEN:DC DKK 28.38B 362M
Glaxosmithkline GSK:US GBP 20.77B 520M
Immunogen IMGN:US USD 304.12M 26.3M
Macrogenics MGNX:US USD 222.18M 74.37M
Mirati Therapeutics MRTX:US USD 1.11B 116.82M
Moderna Inc MRNA:US USD 13.43B 866M
Nektar Therapeutics NKTR:US USD 545.97M 53.52M
Neurocrine Biosciences NBIX:US USD 1.45B 248M
Novartis NOVN:VX USD 36.91B 44M
Puma Biotechnology PBYI:US USD 134.28M 11.93M
Seattle Genetics SGEN:US USD 2.8B 42.91M
Takeda 4502:JP JPY 2.6T 149.67B
Ultragenyx Pharmaceutical RARE:US USD 883.9M 128.77M
Xencor XNCR:US USD 675.34M 7.34M
YTE INCY:US USD 4.09B 271.74M